Diasorin received FDA 510(k) clearance for a customizable syndromic GI pathogen multiplex PCR panel for its Liaison Plex system. The Liaison Plex Gastrointestinal Flex Assay detects 24 gastrointestinal bacteria, viruses, and parasites, including pathogens that are often missing from other commercial menus such as Microsporidia, Dientamoeba fragilis, and Strongyloides stercoralis. The key operational message is flexibility: Flex software enables laboratories to tailor testing panels by seasonality, clinical presentation, guideline-aligned use, travel history, and patient immune status. Diasorin said the additional clearance completes the GI “core portfolio” and builds on earlier FDA clearances for Liaison Plex Respiratory Flex and multiple blood culture panels. For oncology diagnostics, Delfi Diagnostics reported clinical utility data for its cfDNA-based FirstLook Lung liquid biopsy assay, finding that the test increased lung cancer screening uptake nearly threefold among patients behind on screening in a cluster-randomized FIRSTLUNG trial. Together, the two diagnostics updates highlight a shared commercial push in biotech: move multiplex testing and liquid biopsy into workflows that change real-world referral and follow-through, not just test results.